Pyxis Oncology’s (PYXS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a $7.00 price target on the stock.

A number of other analysts also recently weighed in on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $7.00 price target on shares of Pyxis Oncology in a research report on Thursday, September 19th. Stephens assumed coverage on shares of Pyxis Oncology in a report on Friday, November 8th. They issued an “overweight” rating and a $13.00 target price on the stock. William Blair lowered shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday. Finally, Stifel Nicolaus started coverage on Pyxis Oncology in a research note on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Pyxis Oncology Stock Down 9.5 %

Shares of Pyxis Oncology stock opened at $1.90 on Thursday. The business has a fifty day simple moving average of $3.64 and a 200 day simple moving average of $3.61. The stock has a market cap of $112.99 million, a PE ratio of -1.84 and a beta of 1.27. Pyxis Oncology has a 12 month low of $1.35 and a 12 month high of $6.85.

Institutional Trading of Pyxis Oncology

Institutional investors have recently modified their holdings of the company. Ikarian Capital LLC bought a new stake in Pyxis Oncology in the 1st quarter valued at approximately $7,082,000. Vanguard Group Inc. raised its holdings in shares of Pyxis Oncology by 7.3% in the first quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock valued at $5,970,000 after purchasing an additional 94,740 shares during the last quarter. Millennium Management LLC lifted its position in shares of Pyxis Oncology by 125.3% in the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after purchasing an additional 743,499 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Pyxis Oncology by 5.5% during the third quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock worth $3,982,000 after purchasing an additional 57,016 shares during the last quarter. Finally, Blue Owl Capital Holdings LP bought a new position in Pyxis Oncology in the second quarter valued at $3,462,000. 39.09% of the stock is currently owned by institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.